The pros and cons of dying tumour cells in adaptive immune responses.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

12 citing papers in PubMed.

1. Single-cell sequencing reveals the tumor immune microenvironment in thyroid cancer: a narrow review.Frontiers in immunology · 2025
   Review
2. Comprehensive scRNA-seq Analysis and Identification of CD8_+T Cell Related Gene Markers for Predicting Prognosis and Drug Resistance of Hepatocellular Carcinoma.Current medicinal chemistry · 2024
   Article
3. Identification of a Novel CD8BMC cancer · 2023
   Article
4. New insights into T-cell exhaustion in liver cancer: from mechanism to therapy.Journal of cancer research and clinical oncology · 2023
   Review
5. Spontaneous cancer remission after COVID-19: insights from the pandemic and their relevance for cancer treatment.Journal of translational medicine · 2023
   Review
6. Classical epithelial-mesenchymal transition (EMT) and alternative cell death process-driven blebbishield metastatic-witch (BMW) pathways to cancer metastasis.Signal transduction and targeted therapy · 2022
   Review
7. Glutamine deprivation impairs function of infiltrating CD8World journal of gastrointestinal oncology · 2022
   Article
8. Cancer Occurrence as the Upcoming Complications of COVID-19.Frontiers in molecular biosciences · 2021
   Review
9. Long Noncoding RNAs, New Critical Regulators in Cancer Immunity.Frontiers in oncology · 2020
   Review
10. Indoleamine 2, 3-Dioxygenase 1 and CD8 Expression Profiling Revealed an Immunological Subtype of Colon Cancer With a Poor Prognosis.Frontiers in oncology · 2020
    Article
11. Genetic and phenotypic difference in CD8Journal of medical genetics · 2019
    Article
12. Long noncoding RNAs in cancer-immunity cycle.Journal of cellular physiology · 2018
    Review

Corrections and comments

• Comment on
  Dying cells actively regulate adaptive immune responses.2017

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as